Advertisement
Medtronic
Subscribe to Medtronic
View Sample

FREE Email Newsletter

Medtronic Launches yet Another Back Pain Neurostim Study

April 11, 2013 2:45 pm | by Mass Device | News | Comments

Medtech titan Medtronic enrolled the initial patients in its SubQStim II pivotal clinical trial, evaluating the use of peripheral nerve stimulation in treatment of chronic back pain. The new study is the latest in a handful of neurostimulation trials launched by the medical device giant as it continues to battle rivals in the market for neurostimulation systems that treat chronic pain.

Medtronic’s Endurant ‘AAA’ Stent Graft Shows Sustained Durability in Complex Patients

April 11, 2013 11:21 am | by Medtronic | News | Comments

Presented to endovascular specialists at the 35th Charing Cross International Symposium in London, a new analysis of clinical data on the Endurant AAA Stent Graft System from Medtronic demonstrates the implanted medical device’s consistent and compelling performance in treating abdominal aortic aneurysms across a range of patient anatomies.

FDA Clears Medtronic's Affinity Fusion Blood Oxygenation System

April 2, 2013 2:49 pm | by Mass Device | News | Comments

Medtronic said the FDA granted 510(k) clearance for its Affinity Fusion blood oxygenator, used during open heart surgery to replace the function of the lungs. The Minneapolis-area medical device company, which is the world's largest pure-play medtech maker, said the Affinity Fusion is designed to filter a patient's blood to remove particles and air during oxygenation.

Advertisement

The Medtronic Foundation Launches Its "Save a Life" Campaign with the Timberwolves' Ricky Rubio

March 15, 2013 1:26 pm | by Mass Device | News | Comments

Rising Timberwolves basketball star Ricky Rubio is the face of the Medtronic (NYSE:MDT) Foundation's new televised public service announcement, " The Heart Rescue Project." This new campaign for sudden cardiac arrest (SCA), the leading cause of death among young athletes, debuted online last month.

With Medtronic Resolute Stent, Interrupting Dual Antiplatelet Therapy After One Month Showed No Increased Safety Risk in Robust Analysis

March 11, 2013 12:18 pm | by The Associated Press | News | Comments

Cardiologists at ACC.13 learned today that patients with coronary artery disease who received a Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) as participants in one of several clinical studies and interrupted or discontinued their dual antiplatelet therapy after one month of the implant procedure showed no increased safety risk through one year of follow-up.

New Data Reinforce Significant Blood Pressure Reduction Sustained to Two Years Using the Symplicity(TM) Renal Denervation System

March 10, 2013 12:18 pm | by The Associated Press | News | Comments

Medtronic, Inc. announced 24-month data from Symplicity HTN-2, the first randomized clinical trial investigating renal denervation. Presented for the first time today at the 62nd Annual Scientific Session of the American College of Cardiology, the data show patients treated with the Symplicity renal denervation system (n=66) sustained a significant drop in blood pressure.

Medtronic Submits IDE to FDA for U.S. Randomized Clinical Trial for Uncontrolled Hypertension Patients with Systolic Blood Pressure Between 140-160 mm Hg

March 7, 2013 10:19 am | by The Associated Press | News | Comments

Medtronic, announced today that the company has submitted an Investigational Device Exemption to the U.S. FDA to study the Symplicity renal denervation system for the treatment of uncontrolled hypertension in patients with systolic blood pressure between 140-160 mm Hg despite treatment with three or more anti-hypertensive medications of different classes.

Premier Strikes CRM Deals with Medtronic, Boston Scientific, Others

March 6, 2013 12:45 pm | by Mass Device | News | Comments

Group purchasing organization Premier Healthcare Alliance struck a deal with 4 major players in the cardiac device market for several cardiac rhythm management device portfolios. Boston Scientific, Biotronik, Medtronic, and Oscor have all agreed to make certain CRM devices available to customers in the Premier network.

Advertisement

Symplicity(TM) Renal Denervation System One of First Devices Accepted to Participate in Concurrent Review for Joint FDA Premarket Approval and Medicare National Coverage Determination

March 6, 2013 12:18 pm | by The Associated Press | News | Comments

Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) have accepted the inclusion of the Symplicity(TM) renal denervation system for treatment-resistant hypertension in their parallel review program...

Medtronic Announces CE Mark and European Launch of Attain Performa® Portfolio of Quadripolar Leads

March 5, 2013 10:06 am | by The Associated Press | News | Comments

Medtronic, Inc. announced it has received CE (Conformité Européenne) Mark and will begin the European launch of the Attain Performa® portfolio of quadripolar leads. Paired with Medtronic Viva®/Brava® Quad cardiac resynchronization therapy defibrillators, Attain Performa left-heart leads provide additional options for physicians as they navigate different patient anatomies.

Medtronic Announces CE Mark and European Launch of Attain Performa Portfolio of Quadripolar Leads

March 5, 2013 10:06 am | by The Associated Press | News | Comments

Medtronic announced it has received a CE Mark and will begin the European launch of the Attain Performa portfolio of quadripolar leads. Paired with Medtronic Viva/Brava Quad cardiac resynchronization therapy defibrillators, Attain Performa left-heart leads provide additional options for physicians as they navigate different patient anatomies...

Medtronic Approved to Update Resolute Integrity Stent’s CE Mark Labeling on Dual Antiplatelet Therapy

March 4, 2013 10:27 am | by Medtronic | News | Comments

Of relevance to the clinical practice of interventional cardiology, Medtronic announced that it has received regulatory approval to update the CE mark labeling for the Resolute Integrity drug-eluting stent with new information on one month of dual antiplatelet therapy, the shortest minimum duration referenced on the label for any device of its kind.

Medtronic's Irish Profits Rise 119%

February 26, 2013 3:41 pm | by Mass Device | News | Comments

Medtronic's Irish subsidiary posts 119% pre-tax profit growth on a 43% sales increase. One of the largest employers on the Emerald Isle, Medtronic (NYSE:MDT), saw its Irish subsidiary's pre-tax profits surge 119% during its last fiscal year, on sales growth of 43%.

Advertisement

Medtronic Gains First FDA Approval to Conduct Early Feasibility Medical Device Study

February 26, 2013 10:06 am | by The Associated Press | News | Comments

Medtronic, Inc. announced that it has received U.S. Food and Drug Administration (FDA) approval to conduct an early feasibility study using the Medtronic Native Outflow Tract Transcatheter Pulmonary Valve (TPV). This approval represents the first-ever FDA approval of an investigational device exemption (IDE) following the new draft FDA guidance for early feasibility studies.

Medtronic Adds to Intersect ENT's $30M Series D Round

February 25, 2013 12:52 pm | by Mass Device | News | Comments

Medtronic is once again backing sinus implant developer Intersect ENT, this time in a $30 million Series D round led by new investor Norwest Venture Partners. All of Intersect's existing "significant" backers participated in the latest round, including Kleiner Perkins Caufield & Byers, U.S. Venture Partners, PTV Sciences and Medtronic, according to a press release.

Medtronic Cuts Estimated Medical Device Tax Impact in Half

February 19, 2013 5:07 pm | by Mass Device | News | Comments

Medtronic joins fellow medical device giants in forecasting lower 2013 medtech tax costs than previously anticipated. Medical device maker Medtronic (NYSE:MDT) this week became the latest in a string of medtech giants who have pared back their expectations of the impact of the 2.3% medical device sales tax.

Medtronic's Q3 Sales, Earnings Rise

February 19, 2013 8:17 am | by Mass Device | News | Comments

Medtronic posted profit and sales gains during its fiscal 3rd quarter this morning, eating Wall Street analysts' earnings expectations along the way. The Fridley, Minn.-based company, which is the world's largest pure-play medical device company, said profits were up 5.7% on sales growth of 2.8% for the 3 months ended Jan. 25.

Pacemaker Payment Plans, Courtesy of Medtronic

February 5, 2013 7:29 am | by Mass Device | News | Comments

Medtronic offers patients in India the option to pay off a pricey cardiac implants in installments. Medtronic's (NYSE:MDT) India division is offering patients an "easy monthly installment" plan to help families cope with the high cost of cardiac implants. The EMI program is available in 60 hospitals in 18 cities and applies to a handful of medical devices...

Device Tax: We Need Action by Summer, Paulsen Says

February 4, 2013 3:43 pm | by Mass Device | News | Comments

Medical device industry advocate Rep. Erik Paulsen (R-Minn.) says Congress needs to act on the medical device tax by "late spring, early summer" this year. Rep. Erik Paulsen (R-Minn.), an unrelenting opponent of the medical device tax that took effect at the start of the year, still sees avenues for repeal tied to larger discussions of corporate tax reform. News Well, Capitol Hill, Medical Device Taxread more

Biocompatibility and Performance of Medical Devices

January 2, 2013 2:19 pm | Events

Join us for a rare gathering of international thought leaders sharing insights on crucial topics affecting our industries today. This comprehensive symposium is based on the definitive new publication “Biocompatibility and Performance of Medical Devices” assembled by ANSM expert Dr. Jean-Pierre Boutrand.

Biocompatibility and Performance of Medical Devices

January 2, 2013 2:15 pm | Events

Join us for a rare gathering of international thought leaders sharing insights on crucial topics affecting our industries today. This comprehensive symposium is based on the definitive new publication “Biocompatibility and Performance of Medical Devices” assembled by ANSM expert Dr. Jean-Pierre Boutrand.  

Singapore Pumps Innovation into the Heart of Asia’s Growing Cardio Device Industry

December 19, 2012 4:57 pm | by Kevin Lai | Blogs | Comments

In the time it takes to read this piece, 30 Chinese men and women will die from heart disease. This staggering statistic means that as Asia continues to witness astonishing growth and development, Asians will increasingly wrestle with the disease. Heart disease is already the number one killer in China and India, and is fast on the rise throughout Southeast Asia, where the World Health Organization reports that cardiovascular diseases accounts for 27% of all deaths.

Medtronic’s Endurant AAA Stent Graft Delivers Durable Outcomes for Abdominal Aortic Aneursym Repair

November 19, 2012 3:13 pm | by Medtronic | News | Comments

Chosen for nearly one out of every two endovascular abdominal aortic aneurysm repairs worldwide, the Endurant AAA stent graft system from Medtronic, Inc. continues to show robust results in mid-term follow-up, according to two-year clinical data presented at VEITHsymposium, which concluded yesterday in New York.

Medtronic Engages Cardiologists in ‘World Diabetes Day’

October 24, 2012 11:24 am | by Medtronic | News | Comments

Reinforcing its commitment to people with diabetes, Medtronic, Inc. (NYSE: MDT) is promoting its long-standing partnership with the International Diabetes Federation (IDF) through a new initiative surrounding “World Diabetes Day” on Nov. 14 that aims to engage interventional cardiologists worldwide in raising awareness of the connection between diabetes and coronary artery disease.

Medtronic Stent Successfully Treats Long Lesions and Small Vessels, Two Characteristics Typical of Patients with Diabetes, in Multiple Studies

October 23, 2012 11:44 am | by Medtronic | News | Comments

For the treatment of long lesions and small vessels –– two challenging characteristics of coronary artery disease commonly found in patients with diabetes –– the Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) delivered successful clinical results, according to new data presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading